贝伐单抗是全世界第一个抗肿瘤血管生成药物,自2004年美国FDA批准上市以来引起广泛的关注和研究。目前已知其与标准化疗方案联合对于结直肠癌,非小细胞肺癌,肾癌等多种实体瘤有明确疗效,能够显著延长患者生存时间,改善生活质量。但贝伐单抗作为一种靶向治疗药物,其针对的优势人群却始终没有明确。许多学者在此领域进行了探索,本文将就近年关于贝伐单抗疗效预测因素的相关研究结果及存在问题加以综述 Bevacizumab is the world’s first anti-tumor angiogenesis drug, which has aroused extensive attention and research since the FDA approved the listing in 2004. It is known that combined with standard chemotherapy for colorectal cancer, non-small cell lung cancer, renal cell carcinoma and other solid tumors have a clear effect, can significantly prolong survival time and improve quality of life. However, bevacizumab as a targeted therapy, its targeted population has always been not clear. Many scholars have explored in this field. In this paper, we will summarize the related research results and existing problems about the predictors of the efficacy of bevacizumab in recent years